// REFERENCE / concepts
A 39-entry glossary for Blueprint, Don't Die, biomarker protocols, Female-specific Blueprint, source-aware critiques, and tweet-backed concepts that do not yet have dedicated wiki pages.
Source-aware summaries only; not medical advice. Confidence labels describe public-dashboard certainty, not clinical truth.
Johnson summarized an unnamed mouse study reporting restored downstream brain-fluid flow after one intranasal gene therapy; an uncited preclinical lead, not a Blueprint intervention, human treatment, or medical advice.
raw/articles/bryan-johnson/x-twitter-daily-2026-08-14.md A 47-tube blood draw and Baseten event widen Johnson’s molecular and functional measurement surfaces, but publish no results or evidence that the tests are clinically valid, coherent, or actionable.
raw/articles/bryan-johnson/x-twitter-daily-2026-08-13.md + raw/articles/bryan-johnson/x-twitter-daily-2026-08-14.md Johnson describes 14M menstrual-cycle data points, 100+ daily tasks, 50+ devices, and a 12-person medical team before interventions; one intensive N=1 program, not completed female-health evidence or medical advice.
raw/articles/bryan-johnson/x-twitter-daily-2026-07-26.md Johnson says Immortals is adding iPSCs, organoids, deep cellular characterization, and personalized therapy development; company strategy, not evidence of a clinically available diagnosis or cure platform.
raw/articles/bryan-johnson/x-twitter-daily-2026-07-25.md Johnson expands his sauna N=1 into attributed public guidance and reports a 42-to-44 bpm sleep-heart-rate difference after a two-hour meal shift; protocol positioning and personal observation, not validated causal evidence or medical advice.
raw/articles/bryan-johnson/x-twitter-daily-2026-07-24.md Johnson lists Zepbound, Wegovy injections/tablets, Foundayo tablets, compounded tirzepatide, and compounded semaglutide for weight loss and longevity; commercial positioning, not proof of formulation status, availability, or longevity safety and efficacy.
raw/articles/bryan-johnson/x-twitter-daily-2026-07-23.md Johnson calls a dish-grown reprogrammed-cell model a newborn “clone” and proposes therapy testing, organ growth, and young-cell transplantation; speculative positioning without evidence of a human clone, clinically available organ platform, or outcome.
raw/articles/bryan-johnson/x-twitter-daily-2026-07-22.md Johnson reports a $1,800 specialty-lab panel across 15 tear biomarkers for ocular-surface tracking; a concrete measurement plan without results, diagnosis, intervention, validated clinical utility, or reader guidance.
raw/articles/bryan-johnson/x-twitter-daily-2026-07-22.md Johnson says an unspecified incurable-disease diagnosis shifted his project from longevity staples toward disease resolution and frontier biotech; a strategic agenda without named targets, therapies, outcomes, or reader guidance.
raw/articles/bryan-johnson/x-twitter-daily-2026-07-21.md Johnson projects three measured cycles, 50+ devices, 1,900 biomarkers, and 14.8M data points to make female biology “legible”; a planned N=1 program, not completed evidence or medical advice.
raw/articles/bryan-johnson/x-twitter-daily-2026-07-16.md Johnson uses resting heart rate as a behavioral-control proxy for evening pre-commitments; useful algorithmic-health framing, not a universal 41 bpm target or diagnosis.
raw/articles/bryan-johnson/x-twitter-daily-2026-07-16.md Johnson says removing harms has been his best-performing longevity therapy; useful as a foundations-first decision pattern, not quantified proof for every listed exposure or the safety of his wider stack.
raw/articles/bryan-johnson/x-twitter-daily-2026-07-11.md Johnson says an endo-specific ultrasound, AI-assisted pelvic MRI, and microRNA/protein blood test converged on a non-surgical endometriosis diagnosis; useful as a multi-modality measurement case study, not medical advice or cure evidence.
raw/articles/bryan-johnson/x-twitter-daily-2026-07-10.md Johnson proposed a staged AIG cure attempt using live T-cell matching, biweekly blood/wearable monitoring, cryopreserved immune cells, and ex-vivo therapy tests; roadmap evidence, not an approved cure.
raw/articles/bryan-johnson/x-twitter-daily-2026-07-09.md Johnson recast his AIG story as an 11-year low-ferritin diagnostic miss and reported Monoferric ferritin follow-up; useful as measurement ethos, not iron-treatment advice.
raw/articles/bryan-johnson/x-twitter-daily-2026-07-08.md Johnson says he is sequencing 1M immune cells to identify autoreactive clones behind autoimmune gastritis; a cellular/receptor-level measurement layer, not a proven therapy or reader recommendation.
raw/articles/bryan-johnson/x-twitter-daily-2026-07-04.md Johnson reported a negative 71-gene Invitae inherited-cancer panel with DNA plus RNA analysis; useful as a risk-stratification measurement signal, not clinical screening advice.
raw/articles/bryan-johnson/x-twitter-daily-2026-06-26.md Johnson’s June 24 essay defines immortality as life expectancy gains outpacing aging and introduces the Die Economy vs Don’t Die Economy frame; important ideology, not validation of the 2039 forecast.
raw/articles/bryan-johnson/x-twitter-daily-2026-06-25.md Johnson argues divergent wearable numbers can still be useful for within-device trend tracking; this supports longitudinal measurement while leaving accuracy questions open.
raw/articles/bryan-johnson/x-twitter-daily-2026-06-25.md Johnson’s June 23 essay frames blood draws, wearables, and imaging as chemical/functional/structural measurement layers; useful methodology signal, not proof the device improves outcomes.
raw/articles/bryan-johnson/x-twitter-daily-2026-06-24.md Johnson suggests at most one international trip per quarter based on his travel biomarker recovery; N=1 behavioral prescription, not clinical guidance.
raw/articles/bryan-johnson/x-twitter-daily-2026-06-24.md Johnson announced semaglutide/Wegovy, tirzepatide/Zepbound, SGLT2 inhibitors, peptide complexes, glutathione, and NAD+ as part of a wider Immortals Rx catalog; commercial platform news, not medication advice.
raw/articles/bryan-johnson/x-twitter-daily-2026-06-23.md Johnson explicitly says the company has changed its name to Immortals; notable as movement/brand positioning, not a medical claim.
raw/articles/bryan-johnson/x-twitter-daily-2026-06-20.md A June 2026 N=1 skin-aging metric claim after Australia travel; useful as protocol readout context, not independent validation.
raw/articles/bryan-johnson/x-twitter-daily-2026-06-20.md The measurement-led routine and intervention stack Johnson presents as Blueprint.
concepts/blueprint-protocol.md A June 2026 microbiome supplement launch; notable as product expansion, not clinical validation.
raw/articles/bryan-johnson/x-twitter-daily-2026-06-19.md Johnson’s N=1 circadian recovery claim using glucose as readout after Australia travel.
raw/articles/bryan-johnson/x-twitter-daily-2026-06-19.md The feedback-loop idea that biomarkers guide protocol changes, with caveats about outcomes.
concepts/biomarker-driven-longevity-protocols.md A June 2026 N=1 test using ingestible temperature tracking and blood biomarkers; useful as protocol design, not medical advice.
raw/articles/bryan-johnson/x-twitter-daily-2026-06-17.md Delegating health decisions to measurement, rules, and repeatable systems.
concepts/algorithmic-health.md Johnson’s anti-death ideology and movement framing.
concepts/dont-die.md An aspirational longevity claim that should stay clearly low-confidence.
concepts/immortality-by-2039.md The company/protocol ecosystem around Johnson’s routine, products, and measurement claims.
entities/project-blueprint.md The public brand/entity layer for products, protocol content, and community positioning.
entities/blueprint.md A cycle-aware baseline project; source-aware because no dedicated synthesized wiki page exists yet.
queries/bryan-johnson-recent-news-changelog.md + raw X/Kate articles Johnson’s enhancement-competition framing, not independent safety validation.
raw/articles/bryan-johnson/x-twitter-daily-2026-05-25.md The principle that a protocol can reverse or pause interventions when measurements or risk assessments change.
raw/articles/bryan-johnson-x-paused-metformin-2025-08-07.md The critique that biomarker improvements do not automatically prove better long-term outcomes.
raw/articles/bryan-johnson/years-biomarkers-limits-2026-04-20.md The broader ideology tying health, survival, AI-era alignment, and anti-entropic framing together.
raw/articles/bryan-johnson-x-targeted-searches-2026-05-22.md